Terbutaline and the prevention of nocturnal hypoglycemia in type 1 diabetes.

Objective: Bedtime administration of 5.0 mg of the beta(2)-adrenergic agonist terbutaline prevents nocturnal hypoglycemia but causes morning hyperglycemia in type 1 diabetes. We tested the hypothesis that 2.

Basal insulin, glucagon, and growth hormone replacement.

Conclusions drawn from the pancreatic (or islet) clamp technique (suppression of endogenous insulin, glucagon, and growth hormone secretion with somatostatin and replacement of basal hormone levels by intravenous infusion) are critically dependent on the biological appropriateness of the selected doses of the replaced hormones. To assess the appropriateness of representative doses we infused saline alone, insulin (initially 0.20 mU.

Glucagon, in concert with insulin, supports the postabsorptive plasma glucose concentration in humans.

Objective: Given the interest in glucagon antagonism as a potential treatment of diabetes, we tested the hypothesis that glucagon, in concert with insulin, supports the postabsorptive plasma glucose concentration in humans.

Research Design And Methods: Following preliminary studies that indicated that a peripheral intravenous insulin dose of 0.1 mU x kg(-1) x min(-1) (lower than those used previously) provides basal insulin replacement and that a glucagon dose of 1.

Nocturnal hypoglycemia in type 1 diabetes: an assessment of preventive bedtime treatments.

Objective: We assessed four putative bedtime treatments in the prevention of nocturnal hypoglycemia in type 1 diabetes.

Research Design And Methods: Plasma glucose concentrations were measured every 15 min from 2200 h through 0700 h in 21 patients with type 1 diabetes (mean +/- sd HbA(1C) = 7.1 +/- 1.

Coexistence of a pituitary macroadenoma and pheochromocytoma--a case report and review of the literature.

A 59-year old man, who had a hypertensive crisis during transsphenoidal surgery for a pituitary macroadenoma, was subsequently found to have an adrenal pheochromocytoma. A total of twenty-five cases describing the coexistence of a pituitary adenoma and pheochromocytoma have been reported in the literature over the past 40 years. Among pituitary tumors, acromegaly has been the most common.